Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study

MLA

Caiyun Nie, et al. “Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.” Frontiers in Oncology, vol. 12, July 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.885350.

APA

Caiyun Nie, Yunduan He, Huifang Lv, Ming Gao, Xiaohui Gao, Beibei Chen, Weifeng Xu, Jianzheng Wang, Yingjun Liu, Jing Zhao, & Xiaobing Chen. (2022). Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.885350

Chicago

Caiyun Nie, Yunduan He, Huifang Lv, Ming Gao, Xiaohui Gao, Beibei Chen, Weifeng Xu, et al. 2022. “Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.” Frontiers in Oncology 12 (July). doi:10.3389/fonc.2022.885350.